<DOC>
	<DOCNO>NCT00046254</DOCNO>
	<brief_summary>The purpose study evaluate whether zoledronic acid give yearly two year men woman surgical repair recent hip fracture significantly reduce rate re-occurring ( new ) osteoporotic fracture . All patient receive vitamin D calcium .</brief_summary>
	<brief_title>Evaluating Ability Zoledronic Acid Reduce Rate Subsequent Osteoporotic Fractures After Hip Fracture</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Osteoporotic Fractures</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male female age 50 year old Must recent hip fracture repair past 90 day Must able walk without assistive device ( example , use walker ) prior hip fracture Current bisphosphonate user aredia ( pamidronate ) , didronel ( etidronate ) , fosamax ( alendronate ) , actonel ( residronate ) , skelid ( tiludronate ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hip fracture</keyword>
	<keyword>recurrent fracture</keyword>
	<keyword>fracture</keyword>
	<keyword>bone loss</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>geriatrics</keyword>
	<keyword>rehabilitation</keyword>
	<keyword>elderly</keyword>
	<keyword>nursing home</keyword>
	<keyword>orthopedic</keyword>
</DOC>